Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals Inc (MDGL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.128x
Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) has a cash flow conversion efficiency ratio of 0.128x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($79.85 Million) by net assets ($625.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Madrigal Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Madrigal Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Madrigal Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Madrigal Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United Bankshares Inc
NASDAQ:UBSI
|
0.025x |
|
Capstone Mining Corp
TO:CS
|
0.029x |
|
Persistent Systems Limited
NSE:PERSISTENT
|
0.052x |
|
YANGTZE OPT.FIB.AND CAB.H
F:1YO
|
N/A |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
-1.997x |
|
Mohawk Industries Inc
NYSE:MHK
|
0.055x |
|
GALDERMA GROUP AG
NYSE:GALDY
|
N/A |
|
China XD Electric Co Ltd
SHG:601179
|
0.024x |
Annual Cash Flow Conversion Efficiency for Madrigal Pharmaceuticals Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Madrigal Pharmaceuticals Inc from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $754.38 Million | $-455.57 Million | -0.604x | +24.50% |
| 2023-12-31 | $405.33 Million | $-324.23 Million | -0.800x | +29.78% |
| 2022-12-31 | $197.39 Million | $-224.86 Million | -1.139x | -21.47% |
| 2021-12-31 | $196.11 Million | $-183.92 Million | -0.938x | -42.84% |
| 2020-12-31 | $239.97 Million | $-157.56 Million | -0.657x | -557.10% |
| 2019-12-31 | $416.56 Million | $-41.62 Million | -0.100x | -86.86% |
| 2018-12-31 | $476.98 Million | $-25.51 Million | -0.053x | +56.33% |
| 2017-12-31 | $182.26 Million | $-22.32 Million | -0.122x | +74.68% |
| 2016-12-31 | $36.41 Million | $-17.61 Million | -0.484x | +65.88% |
| 2015-12-31 | $50.41 Million | $-71.44 Million | -1.417x | -16.97% |
| 2014-12-31 | $65.14 Million | $-78.92 Million | -1.212x | +23.16% |
| 2013-12-31 | $49.09 Million | $-77.41 Million | -1.577x | -118.66% |
| 2012-12-31 | $75.07 Million | $-54.13 Million | -0.721x | +77.47% |
| 2011-12-31 | $14.77 Million | $-47.30 Million | -3.202x | -96.78% |
| 2010-12-31 | $23.48 Million | $-38.20 Million | -1.627x | -51.17% |
| 2009-12-31 | $24.91 Million | $-26.81 Million | -1.076x | -266.77% |
| 2008-12-31 | $-58.79 Million | $-37.94 Million | 0.645x | -40.98% |
| 2007-12-31 | $24.90 Million | $27.22 Million | 1.093x | -96.39% |
| 2006-12-31 | $-1.75 Million | $-52.98 Million | 30.329x | +2671.96% |
| 2005-12-31 | $52.48 Million | $-61.88 Million | -1.179x | -311.59% |
| 2004-12-31 | $117.96 Million | $-33.80 Million | -0.287x | +6.70% |
| 2003-12-31 | $76.89 Million | $-23.61 Million | -0.307x | -- |